[1] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023, 77(4): 1335-1347. [2] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol, 2020, 73(1): 202-209. [3] Yip TC, Fan JG, Wong VW. China'sfatty liver crisis: A looming public health emergency. Gastroenterology, 2023,165(4):825-827. [4] Schaefer EJ, Anthanont P, Diffenderfer MR, et al. Diagnosis and treatment of high density lipoprotein deficiency. Prog Cardiovasc Dis, 2016, 59(2):97-106. [5] Hayden MR, Clee SM, Brooks-Wilson A, et al. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol, 2000, 11(2):117-122. [6] Akbulut UE, Emeksiz HC, Citli S, et al. IL-17A, MCP-1, CCR-2, and ABCA1 polymorphisms in children with non-alcoholic fatty liver disease. J Pediatr (Rio J), 2019, 95(3):350-357. [7] Ghanem SE, Elsabaawy MM, Abdelkareem MM, et al. Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients. Endocrinol Diabetes Metab, 2023, 6(1):e394. [8] Singh V, Sharma R, Kumar A, et al. Low high-density lipoprotein cholesterol: current status and future strategies for management. Vasc Health Risk Manag, 2010,6:979-996. [9] Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci, 2023, 24(2):1703. |